Results 141 to 150 of about 77,084 (260)

Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer. [PDF]

Biomedicines
Correa Gonzalez B, Karthikeyan A, Moore LA, Bhaumik A, Sandoval E, Hardy M, McPherson JD, Li H, Parikh M, Dall'Era M, Gao AC, Lombard AP.   +11 more
europepmc   +1 more source

Carbon dots as a smart nanoplatform for the blood‐brain barrier penetration and ischemic stroke therapy

Responsive Materials, EarlyView.
This review presents the structure and transport routes of the blood‐brain barrier, summarizes the ischemic stroke pathophysiological cascade, and discusses the BBB‐crossing mechanisms and multitarget therapeutic effects of carbon dots, demonstrating their promising theranostic potential for ischemic stroke.
Yanhan Huang, Xuan Hou, Haiping Zhao, Qi Kong, Xiayan Wang, Xiaokun Geng, Zaicheng Sun   +6 more
wiley   +1 more source

Physiologically-Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib. [PDF]

CPT Pharmacometrics Syst Pharmacol
Lewis GJ, Jewell RC, Krishnatry AS, Taskar KS.   +3 more
europepmc   +1 more source

A single‐molecule prodrug synergistically suppresses MYC‐amplified osteosarcoma through sequential nitric oxide release and photodynamic therapy

Smart Molecules, EarlyView.
A cascade‐responsive small‐molecule prodrug (DHU‐NO3) sequentially releases methylene blue (triggered by reactive oxygen species) and nitric oxide (controlled by 405 nm light), enabling precise spatiotemporal coordination of photodynamic therapy and NO gas therapy to effectively inhibit MYC‐amplified osteosarcoma growth.
Shuxin Peng, Jiangpeng Wu, Shasha Wang, Ying Gao, Xuran Guo, Mengpan Li, Youjin Wu, Yun Wang, Zhengdong Cai, Yingqi Hua, Peng Wei, Yinghua Gao, Tao Yi   +12 more
wiley   +1 more source

CDK9 degrader induces BRCAness and sensitizes castration-resistant prostate cancer to PARP inhibitor. [PDF]

Theranostics
Li J, Sun J, Tan W, Li G, Xiao W, Wu J, Yang W, Chen C, Li Y, Liu J, Liu Y, Liu D, Chen XH, Zhu R, Huang R, Yan J.   +15 more
europepmc   +1 more source

Inhibition of HMGA2 Leads to Reduced Cell Proliferation and Increased Apoptosis in Human Embryonal Carcinoma Cell Lines

Andrology, EarlyView.
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino, Matteo Lampitto, Alfredo Fusco, Marco Barchi, Francesco Esposito, Paolo Chieffi   +5 more
wiley   +1 more source

First-in-Human Study of the PARP Inhibitor HWH340 in Advanced Solid Tumors with Enrichment for Homologous Recombination Repair Gene Mutations. [PDF]

Drug Des Devel Ther
Zhang J, Wang X, Xu H, Zang A, Zhao J, Chen J, Lei R, Zhang Z, Hao C, Liu Y, Zhou R, He L, Sun T, Ouyang Q, Chen S, Xu J, Zhou W, Shi Y, Tong Z.   +18 more
europepmc   +1 more source

CD47 promotes myeloma cell growth through JAK–STAT3/MYC signalling and is targetable by ruxolitinib

British Journal of Haematology, EarlyView.
Summary Cluster of differentiation 47 (CD47), a ‘don't eat me’ immune checkpoint receptor, is frequently overexpressed on multiple myeloma (MM) cells and contributes to immune evasion. While its immune regulatory function is well established, the intrinsic oncogenic role of CD47 remains poorly understood.
Omar Faruq, Deepak Iyer, Patrick Wang, Mariusz Shrestha, Cuihong Wei, Aaron D. Schimmer, Hong Chang   +6 more
wiley   +1 more source

Targeting SLC1A5-mediated glutamine metabolism overcomes PARP inhibitor resistance in ovarian cancer. [PDF]

Cell Death Dis
Han F, Du H, Tian K, Qi G, Kong B, Luo X, Ma H.   +6 more
europepmc   +1 more source

PARP inhibitor maintenance in first-line ovarian cancer therapy: emerging standards and strategies to overcome resistance. [PDF]

Am J Cancer Res
Chen H.
europepmc   +1 more source